NanoRepro AG (NNGRF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
NanoRepro AG (NNGRF) trades at $12.76. NanoRepro AG develops and distributes rapid diagnostic tests and food supplements for home and professional use. Market cap: $164.30M, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for NNGRF: NNGRF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NNGRF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
NNGRF: 1/1 perspectives are bearish.
How is this calculated? →NanoRepro AG (NNGRF) Healthcare & Pipeline Overview
NanoRepro AG focuses on rapid diagnostic tests and food supplements, catering to home and professional users across family planning, disease detection, and food intolerance sectors. Headquartered in Germany, the company distributes its products both domestically and internationally, operating in a competitive healthcare market.
What Is the Investment Thesis for NNGRF?
NanoRepro AG presents a focused investment opportunity within the rapid diagnostics and food supplement sectors. With a market capitalization of $164.30M, the company operates in a growing market for home and professional healthcare solutions. Key value drivers include the expansion of its product line, particularly in infectious disease testing, and its international distribution network. Growth catalysts include increasing demand for rapid diagnostics and the potential for new product approvals. The company's negative P/E ratio of -10.68 and a negative profit margin of -33.4% indicate financial challenges. However, a gross margin of 43.2% suggests potential for improved profitability with increased sales volume and cost management. Investors should monitor the company's ability to scale its operations, manage its expenses, and capitalize on market opportunities.
Based on FMP financials and quantitative analysis
NNGRF Key Highlights
- Market capitalization of $164.30M indicates NanoRepro AG's current valuation in the market.
- Negative P/E ratio of -10.68 reflects the company's current lack of profitability.
- Profit margin of -33.4% highlights the challenges in achieving profitability.
- Gross margin of 43.2% demonstrates the potential for profitability with efficient cost management.
- Beta of -2.94 suggests the stock price moves inversely to the market, potentially offering diversification benefits.
Who Are NNGRF's Competitors?
NNGRF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADOCY Adocia S.A. | $11.80 | +0.00% | $170.44M | 56 |
| AMCY ACS Global, Inc. | $3.00 | -40.00% | $171.27M | 46 |
| AMGXF AnGes, Inc. | $0.36 | +0.00% | $142.50M | 59 |
| BRNHF Broncus Holding Corporation | $0.31 | +283.75% | $161.66M | 50 |
| CMXC Cell MedX Corp. | $0.42 | +0.00% | $126.33M | 44 |
| PRE Prenetics Global Limited | $17.25 | +1.88% | $293.23M | 69 |
| EPGNY Epigenomics AG | $2.39 | +0.00% | 68 | |
| STRRP Star Equity Holdings, Inc. | $9.89 | -0.10% | $40.58M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NNGRF's Key Strengths?
- Diverse product portfolio of rapid diagnostic tests and food supplements.
- Established distribution network in Germany and internationally.
- Focus on innovative and convenient healthcare solutions.
- Expertise in developing and manufacturing rapid diagnostic tests.
What Are NNGRF's Weaknesses?
- Negative profitability and high operating expenses.
- Limited brand recognition compared to larger competitors.
- Dependence on regulatory approvals for new products.
- Small number of employees.
What Could Drive NNGRF Stock Higher?
- Potential regulatory approvals for new rapid diagnostic tests.
- Expansion of distribution network into new geographic markets.
- Increasing demand for rapid diagnostic tests due to healthcare awareness.
- Strategic partnerships with healthcare providers and pharmacies.
- Development of innovative point-of-care testing solutions.
What Are the Key Risks for NNGRF?
- Negative return on equity (-4.6%) — the business is not currently generating profit on shareholder capital.
- Intense competition from larger and more established companies.
- Regulatory changes and healthcare policy reforms.
- Economic downturns and fluctuations in consumer spending.
- Product liability claims and recalls.
- Negative profitability and high operating expenses.
What Are the Growth Opportunities for NNGRF?
- Expansion of Rapid Diagnostic Test Portfolio: NanoRepro AG has the opportunity to expand its portfolio of rapid diagnostic tests to cover a broader range of diseases and health conditions. The global rapid diagnostics market is projected to reach $40 billion by 2028, driven by the increasing need for quick and accurate diagnostic solutions. By investing in research and development, NanoRepro can introduce new tests for infectious diseases, chronic conditions, and other health concerns, capturing a larger share of this growing market. Timeline: 1-3 years.
- Strategic Partnerships and Distribution Agreements: NanoRepro AG can pursue strategic partnerships and distribution agreements to expand its market reach and access new customer segments. Collaborating with established healthcare providers, pharmacies, and online retailers can help the company increase its product visibility and sales volume. The global healthcare distribution market is estimated at $800 billion, offering significant opportunities for NanoRepro to leverage existing distribution networks. Timeline: Ongoing.
- Geographic Expansion into New Markets: NanoRepro AG can expand its geographic presence beyond Germany and international markets to tap into new growth opportunities. Emerging markets in Asia, Latin America, and Africa offer significant potential for rapid diagnostic tests and food supplements, driven by increasing healthcare awareness and disposable incomes. By adapting its product offerings to local needs and preferences, NanoRepro can establish a foothold in these markets and drive revenue growth. Timeline: 3-5 years.
- Development of Innovative Point-of-Care Testing Solutions: NanoRepro AG can focus on developing innovative point-of-care testing solutions for hospitals, clinics, and other healthcare settings. The point-of-care diagnostics market is projected to reach $50 billion by 2025, driven by the increasing demand for rapid and convenient diagnostic testing at the patient's bedside. By investing in research and development, NanoRepro can introduce new point-of-care tests for critical conditions such as cardiac events, infections, and metabolic disorders. Timeline: 2-4 years.
- Leveraging Online Sales Channels and E-commerce Platforms: NanoRepro AG can further leverage online sales channels and e-commerce platforms to reach a wider customer base and drive revenue growth. The global e-commerce market for healthcare products is experiencing rapid growth, driven by the increasing adoption of online shopping and the convenience of home delivery. By optimizing its online presence, offering competitive pricing, and providing excellent customer service, NanoRepro can capture a larger share of this growing market. Timeline: Ongoing.
What Opportunities Does NNGRF Have?
- Expansion into new geographic markets and customer segments.
- Development of innovative point-of-care testing solutions.
- Strategic partnerships and distribution agreements.
- Increasing demand for rapid diagnostic tests and food supplements.
What Threats Does NNGRF Face?
- Intense competition from larger and more established companies.
- Regulatory changes and healthcare policy reforms.
- Economic downturns and fluctuations in consumer spending.
- Product liability claims and recalls.
What Are NNGRF's Competitive Advantages?
- Proprietary rapid diagnostic test technologies.
- Established distribution network in Germany and internationally.
- Brand reputation for quality and reliability.
- Diverse product portfolio targeting multiple healthcare segments.
What Does NNGRF Do?
NanoRepro AG, based in Marburg, Germany, develops, manufactures, and distributes rapid diagnostic tests and food supplements. Founded with the vision of providing accessible and convenient healthcare solutions, the company has evolved to offer a diverse range of products targeting both home and professional users. NanoRepro's product portfolio includes rapid diagnostic tests for family planning, disease detection (including HIV, influenza, and COVID-19), and food intolerances. These tests are available through online shops and pharmacies. The company's rapid diagnostic tests cover areas such as allergy testing, family planning, and preventive healthcare. For professional use in hospitals and medical practices, NanoRepro offers point-of-care testing products for detecting conditions like HIV, cardiac Troponin I, and D-dimer. Additionally, the company provides immunochromatographic lateral flow tests for biomarker detection. NanoRepro also offers a range of food supplements tailored for both men and women, expanding its reach into the wellness market. The company distributes its products across Germany and internationally, positioning itself as a provider of accessible and convenient healthcare solutions.
What Products and Services Does NNGRF Offer?
- Develops rapid diagnostic tests for home and professional use.
- Manufactures rapid diagnostic tests for various applications.
- Distributes rapid diagnostic tests in Germany and internationally.
- Offers products for family planning and disease detection.
- Provides tests for food intolerances and allergies.
- Sells food supplements for men and women.
- Offers point-of-care testing products for hospitals and medical practices.
How Does NNGRF Make Money?
- Develops and manufactures rapid diagnostic tests and food supplements.
- Sells products directly to consumers through online shops.
- Distributes products through pharmacies and healthcare providers.
- Generates revenue from the sale of rapid diagnostic tests and food supplements.
What Industry Does NNGRF Operate In?
NanoRepro AG operates within the medical diagnostics and research industry, a sector experiencing growth driven by increasing demand for rapid and point-of-care testing solutions. The global market for rapid diagnostics is projected to continue expanding, fueled by technological advancements and a growing emphasis on preventive healthcare. NanoRepro competes with companies like ADOCY (Adocia SA), AMCY (Amgen Inc), AMGXF (Amgen Korea Ltd), BRNHF (Brainstorm Cell Therapeutics Inc), and CMXC (CMC Materials Inc), each with its own focus and market presence. The competitive landscape is characterized by innovation, regulatory approvals, and market access.
Who Are NNGRF's Key Customers?
- Consumers seeking rapid diagnostic tests for home use.
- Healthcare professionals in hospitals and medical practices.
- Pharmacies and retailers selling diagnostic tests and food supplements.
- Individuals looking for food supplements for general wellness.
ROE -5%Key Financial Metrics
Return on equity for NanoRepro AG stands at -4.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -4.5%, showing how much profit it generates from its asset base. Its free cash flow yield is 9.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 32.12 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -6.5%, the inverse of the P/E and a quick read on earnings relative to price.
NanoRepro AG (NNGRF) Valuation Context
Valued at $164.30M, NNGRF is classified as a micro-cap stock.
Company Profile
NanoRepro AG operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Marburg, DE. The company is led by CEO Lisa Jungst. NNGRF has traded publicly since 2021.
F-Score 4/9Financial Health
NanoRepro AG's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 97.75 places it in the safe zone, indicating low near-term bankruptcy risk.
NNGRF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests those with the most knowledge of the company see value, potentially indicating positive future developments.
- The community is buzzing about potential partnerships, and that kind of optimism can drive momentum.
- There's a growing narrative that NanoRepro is undervalued compared to its peers, which could attract bargain hunters.
- Positive chatter about upcoming product releases has created a sense of anticipation and potential growth.
Bear Case
- Insider activity, while showing some buying, is not overwhelmingly positive, suggesting some internal uncertainty remains.
- Community sentiment is highly speculative, and the hype might not translate into real-world results.
- The market perception of NanoRepro is still largely unknown, meaning it could be a while before it gains significant traction.
- There are concerns about the company's ability to scale production to meet potential demand, which could hinder growth.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
NNGRF Latest News
No recent news available for NNGRF.
NNGRF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NNGRF.
Price Targets
Wall Street price target analysis for NNGRF.
NNGRF MoonshotScore
What does this score mean?
The MoonshotScore rates NNGRF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Lisa Jungst
CEO
Lisa Jungst serves as the CEO of NanoRepro AG, leading a team of 17 employees. Her background includes experience in management and operations. She has focused on strategic development and market expansion. Jungst's leadership is geared towards enhancing NanoRepro's market position and driving growth through innovative product offerings and strategic partnerships. Her expertise is in navigating the healthcare industry and positioning the company for future success.
Track Record: Under Lisa Jungst's leadership, NanoRepro AG has focused on expanding its product portfolio and strengthening its distribution network. Key milestones include the introduction of new rapid diagnostic tests and the expansion of online sales channels. Jungst has also overseen efforts to improve operational efficiency and reduce costs. Her strategic decisions have aimed to position NanoRepro as a provider of accessible and convenient healthcare solutions.
NNGRF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that NanoRepro AG may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and regulatory oversight.
- Potential for illiquidity and price volatility.
- Higher risk of fraud and manipulation.
- Limited access to capital and financing options.
- Dependence on a small number of key customers or products.
- Verify the company's financial statements and SEC filings.
- Research the company's management team and board of directors.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Check for any history of regulatory issues.
- Development and distribution of rapid diagnostic tests and food supplements.
- Operations in Germany and internationally.
- Presence in the healthcare sector.
- CEO leadership by Lisa Jungst.
- Company headquarters in Marburg, Germany.
What Investors Ask About NanoRepro AG (NNGRF) — Healthcare
What does NanoRepro AG do?
NanoRepro AG develops, manufactures, and distributes rapid diagnostic tests and food supplements for both home and professional use. The company's product portfolio includes tests for family planning, disease detection, food intolerances, and allergies. NanoRepro serves consumers directly through online shops and distributes its products through pharmacies and healthcare providers. The company operates primarily in Germany and internationally, focusing on providing convenient and accessible healthcare solutions.
What do analysts say about NNGRF stock?
As of March 17, 2026, there is no readily available analyst consensus on NanoRepro AG (NNGRF) due to its OTC listing and smaller market capitalization. Key valuation metrics to consider include the company's market capitalization of $164.30M, negative P/E ratio of -10.68, and gross margin of 43.2%. Growth considerations involve the company's ability to expand its product line, increase its market reach, and achieve profitability. Investors should conduct their own due diligence and consult with a financial advisor before making any investment decisions.
What are the main risks for NNGRF?
NanoRepro AG faces several risks, including intense competition from larger and more established companies in the medical diagnostics and food supplement industries. Regulatory changes and healthcare policy reforms could impact the company's ability to market and sell its products. Economic downturns and fluctuations in consumer spending could reduce demand for its products. Product liability claims and recalls pose a risk to the company's reputation and financial performance. The company's negative profitability and high operating expenses also present a significant risk.
What are the key factors to evaluate for NNGRF?
Evaluate NNGRF on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does NNGRF data refresh on this page?
NNGRF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven NNGRF's recent stock price performance?
NanoRepro AG (NNGRF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio of rapid diagnostic tests and food supplements. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NNGRF overvalued or undervalued right now?
Valuing NanoRepro AG (NNGRF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying NNGRF?
Before investing in NanoRepro AG (NNGRF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC stocks carry higher risks than exchange-listed stocks.